Nipro Medical Corporation is set to introduce its second-generation Cronus high-pressure (HP) percutaneous transluminal angioplasty (PTA) balloon catheter to the US market.
Cronus HP is indicated for use in popliteal, femoral, iliac, and renal arteries, and in the treatment of arteriovenous fistulas (AVFs), with Cronus HP serving as Nipro’s “go-to choice” for vascular surgeons and interventional nephrologists in the repair and restoration of AVFs in haemodialysis patients—according to a press release from the company.
“Vascular access complications happen, even with the greatest of care,” said John O’Connor, director of Vascular Sales at Nipro. “So, we are here to ensure failed fistulas are transformed into functional fistulas.”
The release adds that the characteristics that are foundational to the Cronus HP include strength, flexibility and durability at high pressures, the ability to aid in using only one balloon during a procedure, facilitating entry across the lesion, and helping to minimise ‘balloon dog-boning’ and address difficult stenoses.
“Cronus HP signifies a unique bridge of two worlds within the Nipro product portfolio—renal and vascular,” said Joe Dawson, executive vice president of Nipro. The release also notes that the company’s vascular division, newly established in April 2021, already features nine products across three categories, including intravascular imaging.
